Health Condition 1: E113- Type 2 diabetes mellitus with ophthalmic complications
Conditions
Interventions
Intervention1: Anti-VEGF Injection: The study aims to investigate the association between SD-OCT Biomarkers and the treatment response among Diabetic Macular Oedema eyes treated with intravitreal Anti
Sponsors
Nethradhama Superspeciality Eye Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Pateints with either type 1 or type 2 Diabetes Mellitus aged 18 years or older, who have consented for the study. Centre-Involving Diabetic Macular Oedema (DMO), defined by sub-foveal involvement of abnormal intraretinal and/or subretinal fluid with concurrent thickening affecting the 1mm diameter of CST
Exclusion criteria
Exclusion criteria: 1. Pre-existing retinal or macular disease other than DR or DMO 2. SD-OCT images with porr quality 3. Pre-existing ocular diseases such as cataract, glaucoma, pathological myopia and uveitis 4. Any cataract surgery done in past 3 months 5. Prior vitreoretinal surgery or intravitreal anti-VEGF injections 6. Patients who have undergone any supplementary macular laser and / or intravitreal steroid implants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Morphology of DMO 2. Vitreomacular relationship 3. Presence of DRIL 4. Presence and number of hyperreflective retinal foci 5. Presence of hyper-reflectivity within intra-retinal cyst 6. Visibility and continuity of ELM or EZTimepoint: Taken before injection and at 1 month post injection | — |
Secondary
| Measure | Time frame |
|---|---|
| If there is any improvement in visual acuity of the patientTimepoint: Taken at 3 months & 6 months post injection | — |
Countries
India
Contacts
Public ContactDr Mamatha N
Nethradhama Super Speciality Eye Hospital
Outcome results
None listed